Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals
Epic: EHP
News: Latest news
Web Site: Epistem
Other Articles: 16-03-201009-03-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 09, 07:08Amphion’s Unique Approach to Innovation

Investors in Amphion should should keep an eye on further developments at Kromek. The business could be floated during Q1 2011, at which point Amphion’s 16% stake should be worth far more than the last valuation of £9m.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday September 08, 10:42African Energy Resources encouraged by coal results at Sese, seeks cornerstone partner

With the coal quality, thickness and shallow depth, it augurs well for potential commercial coal production for African Energy at Sese in Botswana.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Tuesday September 07, 08:12MetroCoal re-affirms Columboola coal Resource yet to be completed

Emerging coal-focused energy company MetroCoal (ASX: MTE) has clarified that it has not completed any resource estimate or report on its Columboola Project area in Queensland's Surat Basin.

FULL ARTICLE ►
Epistem

Epistem

Epistem is a biotechnology company applying its expertise in epithelial stem cells in the areas of oncology and gastrointestinal diseases as well as dermatological applications. Epistem has become recognised as a specialist in epithelial tissue and stem cell analyses. Our heritage is based on our expert science and know-how in the field of epithelial tissue and adult epithelial stem cell biology.

CLICK HERE FOR FULL ANLAYSIS OF EPISTEM
Thursday, July 29, 2010

Epistem Holdings issues upbeat trading statement for FY

Stem-cell biotechnology company Epistem Holdings PLC (LON:EHP) said trading over the year to end-June 2010 was in line with market forecasts and the it expects to report a growth in after tax profit from a year earlier.

In a pre-close trading statement, Epistem said sales in all of its business divisions have made strong progress in the period.

It expects to release its final results for the year on October 5 2010.

Epistem specialises in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing contract research services to drug development companies.

The group's core expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

At the interim stage, Epistem revealed the commercial progress being made through its partnership with Novartis as it reported, in March, a 90% year-on-year increase in revenue during the six months ended 31 December 2009. Revenue in the first half saw rose to £2.8m compared with £1.5m in the same period a year earlier.

Epistem broke even in the first half, compared to a £500,000 loss previously, furthermore the company said it anticipates further revenue growth over the second half, to provide an improved financial profile.

AddThis Feed Button
Register here to be notified of future Epistem articles.

Other Epistem news

More news ►

Investors interested in Epistem recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.